Alpha Tau Medical to Discuss Interim Data on Brain Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 39 minutes ago
0mins
Should l Buy DRTS?
Source: stocktwits
- Clinical Trial Progress: Alpha Tau Medical is set to discuss interim data from its U.S. Regain study involving three patients, evaluating Alpha DaRT for recurrent glioblastoma, highlighting the company's potential in brain cancer treatment.
- FDA Certification Acceleration: The company has received Breakthrough Device Designation from the FDA and submitted the first section of its pre-market approval application in January, indicating significant progress in regulatory approval that may expedite market entry.
- Positive Market Reaction: Alpha Tau's shares rose over 1% in Monday's trading, despite ending last week slightly lower at $8.51, reflecting strong investor interest in the company's early clinical results and the innovative nature of its treatment.
- Data Presentation Attracts Investors: The updated pancreatic cancer data presented at Digestive Disease Week showed all 19 evaluable patients achieved local disease control with a 21% partial response rate, further boosting investor confidence in the efficacy of Alpha DaRT treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DRTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DRTS
Wall Street analysts forecast DRTS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.850
Low
5.00
Averages
7.00
High
9.00
Current: 7.850
Low
5.00
Averages
7.00
High
9.00
About DRTS
Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alpha Tau Medical to Discuss Interim Data on Brain Cancer Treatment
- Clinical Trial Progress: Alpha Tau Medical is set to discuss interim data from its U.S. Regain study involving three patients, evaluating Alpha DaRT for recurrent glioblastoma, highlighting the company's potential in brain cancer treatment.
- FDA Certification Acceleration: The company has received Breakthrough Device Designation from the FDA and submitted the first section of its pre-market approval application in January, indicating significant progress in regulatory approval that may expedite market entry.
- Positive Market Reaction: Alpha Tau's shares rose over 1% in Monday's trading, despite ending last week slightly lower at $8.51, reflecting strong investor interest in the company's early clinical results and the innovative nature of its treatment.
- Data Presentation Attracts Investors: The updated pancreatic cancer data presented at Digestive Disease Week showed all 19 evaluable patients achieved local disease control with a 21% partial response rate, further boosting investor confidence in the efficacy of Alpha DaRT treatment.
See More
Alpha Tau Announces Interim Clinical Data for Alpha DaRT
- Clinical Trial Announcement: Alpha Tau Medical has scheduled a conference call on May 11, 2026, to discuss interim clinical data from its Alpha DaRT treatment for recurrent glioblastoma, which is expected to provide critical insights for future treatment protocols.
- Patient Recruitment Strategy: The REGAIN trial aims to enroll up to ten patients with recurrent glioblastoma who are not candidates for surgical resection after prior central nervous system radiation, indicating a significant market need for this treatment.
- Technology Overview: The Alpha DaRT technology utilizes intratumoral delivery of radium-224 sources to achieve highly effective irradiation of tumors while minimizing damage to surrounding healthy tissue, showcasing its substantial therapeutic potential.
- Company Growth Prospects: Founded in 2016, Alpha Tau has focused on oncology therapeutics development, and as clinical trials progress, it is expected to enhance its competitive position in the cancer treatment market.
See More
Alpha Tau Completes Enrollment in Pivotal U.S. Trial
- Milestone Enrollment: Alpha Tau has completed enrollment of 88 patients in the ReSTART trial, marking a significant step towards potential FDA pre-market approval, which is expected to accelerate the commercialization of Alpha DaRT.
- Clinical Trial Context: This trial is the first pivotal clinical study in the U.S. for recurrent cutaneous squamous cell carcinoma, building on clinical data from Israel, Italy, and France, demonstrating the efficacy and safety of Alpha DaRT, addressing urgent patient needs for new therapies.
- Treatment Demand: Recurrent cutaneous squamous cell carcinoma is the second most common form of skin cancer, with rising incidence rates, and existing treatment options failing to meet patient needs; Alpha DaRT aims to provide new treatment options for this underserved population.
- Future Outlook: With enrollment complete, the ReSTART trial will proceed to the follow-up phase, and Alpha Tau will continue to advance its modular PMA application, looking forward to the potential market launch of Alpha DaRT in the future.
See More
Alpha Tau Medical Presents New Therapy at Head and Neck Cancer Conference
- Clinical Trial Progress: Alpha Tau Medical's clinical trial at Hadassah Medical Center in Jerusalem evaluates the efficacy of Alpha DaRT in combination with pembrolizumab, particularly targeting elderly patients aged 70 and above, demonstrating the potential of this combination therapy for treating locally advanced and metastatic head and neck squamous cell carcinoma.
- Conference Presentation Opportunity: The abstract of this study has been selected for podium presentation at the American Head and Neck Society International Conference, marking a strategic milestone for the company and showcasing its influence and scientific merit in the global oncology community.
- Addressing Patient Needs: Head and neck cancer is the sixth most common malignancy worldwide, with limited treatment options for elderly patients; the combination of Alpha DaRT as a localized treatment with systemic immunotherapy aims to improve survival rates and quality of life for this vulnerable population, filling existing treatment gaps.
- Safety Profile Advantage: Research from Alpha Tau indicates that Alpha DaRT exhibits a favorable safety profile across all head and neck cancer studies, with generally observed acute low-grade toxicities and no chronic effects reported, enhancing its appeal as an adjunct treatment in existing therapeutic regimens.
See More
Alpha DaRT Achieves Milestone in Pancreatic Cancer Trials
- Local Disease Control Rate: Alpha DaRT achieved a 100% local disease control rate in 19 evaluable patients across two first-in-human trials, highlighting its potential in treating pancreatic cancer, particularly in patients with extremely limited chemotherapy options.
- Favorable Safety Profile: Among 26 subjects treated, only 8 device-associated adverse events were reported, representing a 27% incidence, with nearly all events resolving within two weeks, indicating encouraging safety in heavily pre-treated patients.
- Clinical Integration Design: The therapy is designed for seamless integration into standard GI endoscopy workflows through an endoscopic ultrasound-guided procedure, facilitating easier adoption by clinicians and improving treatment accessibility for patients.
- International Conference Presentation: The clinical results of Alpha DaRT were presented for the first time at the 2026 Digestive Disease Week (DDW) conference, marking a significant recognition in the international gastroenterology field and further enhancing its prospects in pancreatic cancer treatment.
See More
ALPHA TAU REPORTS COMPLETE LOCAL DISEASE CONTROL AND POSITIVE SAFETY PROFILE IN ALPHA DART® PANCREATIC CANCER TRIALS SHOWCASED AT DDW 2026
Local Disease Control Rate: Alpha Tau has announced a 100% local disease control rate in its clinical trials for the Alpha DaRT® pancreatic cancer treatment.
Safety Profile: The trials also demonstrated a favorable safety profile for the treatment, indicating minimal adverse effects on patients.
Presentation at Conference: These findings were presented at the DdW 2026 conference, highlighting the significance of the results in the field of cancer treatment.
Implications for Future Research: The positive outcomes from the trials may pave the way for further research and development of Alpha DaRT® in treating other types of cancer.
See More
Alpha Tau Medical to Discuss Interim Data on Brain Cancer Treatment
- Clinical Trial Progress: Alpha Tau Medical is set to discuss interim data from its U.S. Regain study involving three patients, evaluating Alpha DaRT for recurrent glioblastoma, highlighting the company's potential in brain cancer treatment.
- FDA Certification Acceleration: The company has received Breakthrough Device Designation from the FDA and submitted the first section of its pre-market approval application in January, indicating significant progress in regulatory approval that may expedite market entry.
- Positive Market Reaction: Alpha Tau's shares rose over 1% in Monday's trading, despite ending last week slightly lower at $8.51, reflecting strong investor interest in the company's early clinical results and the innovative nature of its treatment.
- Data Presentation Attracts Investors: The updated pancreatic cancer data presented at Digestive Disease Week showed all 19 evaluable patients achieved local disease control with a 21% partial response rate, further boosting investor confidence in the efficacy of Alpha DaRT treatment.
See More
Alpha Tau Announces Interim Clinical Data for Alpha DaRT
- Clinical Trial Announcement: Alpha Tau Medical has scheduled a conference call on May 11, 2026, to discuss interim clinical data from its Alpha DaRT treatment for recurrent glioblastoma, which is expected to provide critical insights for future treatment protocols.
- Patient Recruitment Strategy: The REGAIN trial aims to enroll up to ten patients with recurrent glioblastoma who are not candidates for surgical resection after prior central nervous system radiation, indicating a significant market need for this treatment.
- Technology Overview: The Alpha DaRT technology utilizes intratumoral delivery of radium-224 sources to achieve highly effective irradiation of tumors while minimizing damage to surrounding healthy tissue, showcasing its substantial therapeutic potential.
- Company Growth Prospects: Founded in 2016, Alpha Tau has focused on oncology therapeutics development, and as clinical trials progress, it is expected to enhance its competitive position in the cancer treatment market.
See More
Alpha Tau Completes Enrollment in Pivotal U.S. Trial
- Milestone Enrollment: Alpha Tau has completed enrollment of 88 patients in the ReSTART trial, marking a significant step towards potential FDA pre-market approval, which is expected to accelerate the commercialization of Alpha DaRT.
- Clinical Trial Context: This trial is the first pivotal clinical study in the U.S. for recurrent cutaneous squamous cell carcinoma, building on clinical data from Israel, Italy, and France, demonstrating the efficacy and safety of Alpha DaRT, addressing urgent patient needs for new therapies.
- Treatment Demand: Recurrent cutaneous squamous cell carcinoma is the second most common form of skin cancer, with rising incidence rates, and existing treatment options failing to meet patient needs; Alpha DaRT aims to provide new treatment options for this underserved population.
- Future Outlook: With enrollment complete, the ReSTART trial will proceed to the follow-up phase, and Alpha Tau will continue to advance its modular PMA application, looking forward to the potential market launch of Alpha DaRT in the future.
See More
Alpha Tau Medical Presents New Therapy at Head and Neck Cancer Conference
- Clinical Trial Progress: Alpha Tau Medical's clinical trial at Hadassah Medical Center in Jerusalem evaluates the efficacy of Alpha DaRT in combination with pembrolizumab, particularly targeting elderly patients aged 70 and above, demonstrating the potential of this combination therapy for treating locally advanced and metastatic head and neck squamous cell carcinoma.
- Conference Presentation Opportunity: The abstract of this study has been selected for podium presentation at the American Head and Neck Society International Conference, marking a strategic milestone for the company and showcasing its influence and scientific merit in the global oncology community.
- Addressing Patient Needs: Head and neck cancer is the sixth most common malignancy worldwide, with limited treatment options for elderly patients; the combination of Alpha DaRT as a localized treatment with systemic immunotherapy aims to improve survival rates and quality of life for this vulnerable population, filling existing treatment gaps.
- Safety Profile Advantage: Research from Alpha Tau indicates that Alpha DaRT exhibits a favorable safety profile across all head and neck cancer studies, with generally observed acute low-grade toxicities and no chronic effects reported, enhancing its appeal as an adjunct treatment in existing therapeutic regimens.
See More
Alpha DaRT Achieves Milestone in Pancreatic Cancer Trials
- Local Disease Control Rate: Alpha DaRT achieved a 100% local disease control rate in 19 evaluable patients across two first-in-human trials, highlighting its potential in treating pancreatic cancer, particularly in patients with extremely limited chemotherapy options.
- Favorable Safety Profile: Among 26 subjects treated, only 8 device-associated adverse events were reported, representing a 27% incidence, with nearly all events resolving within two weeks, indicating encouraging safety in heavily pre-treated patients.
- Clinical Integration Design: The therapy is designed for seamless integration into standard GI endoscopy workflows through an endoscopic ultrasound-guided procedure, facilitating easier adoption by clinicians and improving treatment accessibility for patients.
- International Conference Presentation: The clinical results of Alpha DaRT were presented for the first time at the 2026 Digestive Disease Week (DDW) conference, marking a significant recognition in the international gastroenterology field and further enhancing its prospects in pancreatic cancer treatment.
See More
ALPHA TAU REPORTS COMPLETE LOCAL DISEASE CONTROL AND POSITIVE SAFETY PROFILE IN ALPHA DART® PANCREATIC CANCER TRIALS SHOWCASED AT DDW 2026
Local Disease Control Rate: Alpha Tau has announced a 100% local disease control rate in its clinical trials for the Alpha DaRT® pancreatic cancer treatment.
Safety Profile: The trials also demonstrated a favorable safety profile for the treatment, indicating minimal adverse effects on patients.
Presentation at Conference: These findings were presented at the DdW 2026 conference, highlighting the significance of the results in the field of cancer treatment.
Implications for Future Research: The positive outcomes from the trials may pave the way for further research and development of Alpha DaRT® in treating other types of cancer.
See More
